After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension

  1. Tamargo, J.
Revue:
European heart journal. Cardiovascular pharmacotherapy

ISSN: 2055-6845

Année de publication: 2024

Volumen: 10

Número: 5

Pages: 371-373

Type: Article

DOI: 10.1093/EHJCVP/PVAE035 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus